Docetaxel nanopolymer - Pfizer

Drug Profile

Docetaxel nanopolymer - Pfizer

Alternative Names: BIND-014

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Johns Hopkins University; Yale University
  • Developer BIND Therapeutics; Pfizer
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Non-small cell lung cancer

Highest Development Phases

  • Phase II Cervical cancer; Cholangiocarcinoma; Head and neck cancer; Non-small cell lung cancer; Urogenital cancer
  • No development reported Solid tumours
  • Discontinued Prostate cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (IV, Infusion)
  • 02 May 2016 BIND Therapeutics files for Chapter 11 bankruptcy
  • 13 Apr 2016 BIND Therapeutics terminates the iNSITE2 trial in Urogenital cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease) and Cholangiocarcinoma (Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA and Russia (IV) (NCT02479178)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top